Clinical trials: Human Immunodeficiency Virus I Infection
Healthy
A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults
The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.
- Trial name
- MENSCH (NCT02218125)
- Testing
- MVA Mosaic
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Healthy Subjects, Infection, Human Immunodeficiency Virus
GSK1349572 Drug Interaction Study With Protease Inhibitors
A study in healthy volunteers to determine whether there is a drug interaction between GSK1349572 and the HIV protease inhibitors lopinavir/ritonavir and darunavir/ritonavir
- Trial name
- NCT00774735
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, HCV
VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer
The purpose of this study is to determine the effect of EFV (Efavirenz) and TDF (Tenofovir disoproxil fumarate) on the pharmacokinetics of TVR (Telaprevir) and to determine the effect of TVR on the pharmacokinetics of EFV and…
- Conditions
- Hepatitis C, HCV, HIV, AIDS
- Trial name
- NCT00828789
- Testing
- Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Infection, Human Immunodeficiency Virus I, HIV Infection
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.
- Trial name
- NCT00242840
- Testing
- No intervention; Observational study
- Where
- 7 sites in United States, Italy
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus I, HIV Infection
KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects
Recently, the fixed-dose combinations (FDC) KIVEXA™ (abacavir/lamivudine) and TRUVADA (tenofovir disoproxil fumarate/emtricitabine) have facilitated the usage of once-daily regimens.
- Trial name
- ASSERT (NCT00549198)
- Testing
- Abacavir/lamivudine and efavirenz, Tenofovir/Emtricitabine and efavirenz
- Where
- 68 sites in Austria, Belgium and 11 more
- Volunteers
- 392 people
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency.
- Trial name
- IMID (NCT01704781)
- Testing
- Lenalidomide, Vacc-4X, rhuGM-CSF
- Where
- 4 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Bionor Immuno AS
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1…
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- TURQUOISE-I (NCT01939197)
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 318 people
- Sponsor
- AbbVie
HIV-1
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
The purpose of the study is to determine the safety, tolerability and plasma pharmacokinetics (pk) (i.e., the levels of TMC558445 circulating in your blood over time) of increasing single oral doses of TMC558445 and of multiple…
- Trial name
- NCT00838760
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV I Infection
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.
- Trial name
- REDUC (NCT02092116)
- Testing
- Romidepsin, Vacc-4x, rhuGM-CSF
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Bionor Immuno AS
Healthy Subjects, Infection, Human Immunodeficiency Virus
Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs
The purpose of this study is to evaluate the effect of GSK2448761 on CYP450 metabolic probes and to evaluate the 2-way interaction between GSK2448761 and two ritonavir-boosted protease inhibitors that are commonly used in…
- Trial name
- NCT00920088
- Testing
- darunavir/ritonavir, lopinavir/ritonavir, Midazolam
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Human Immunodeficiency Virus I
Fosamprenavir Versus Other Protease Inhibitors
This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir.
- Trial name
- NCT00094523
- Testing
- Fosamprenavir
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 314 people
- Sponsor
- ViiV Healthcare
HIV Infections, Cytopenias
A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
To determine the maximum tolerated dose (MTD) and toxicity of sargramostim (recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF) given by continuous intravenous infusion (CIV) in patients with leukopenia in…
- Trial name
- NCT00002009
- Testing
- Sargramostim
- Where
- 2 sites in United States
- Sponsor
- Sandoz
HIV Infection
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
The aim of the study is to see if apricitabine or tipranavir affect the levels of each other in the blood (pharmacokinetic interaction) when they are dosed together.
- Trial name
- NCT00352066
- Testing
- apricitabine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Avexa
HIV-1-infection
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults
UB-421 subcutaneous formulation (UB-421 SC) is developed to provide HIV infected patients a more convenient drug delivery method.
- Trial name
- NCT04620291
- Testing
- UB-421 SC
- Volunteers
- 18 people
- Sponsor
- United BioPharma
Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection
HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
The goal of this randomized clinical trial is to evaluate the safety and immunogenicity of the HIV Therapeutic DNA Vaccine (ICVAX) in participants with HIV-1 infection under antiretroviral therapy (ART).
- Trial name
- NCT07530198
- Testing
- ICVAX (TERESA-EPT I device), ICVAX (PharmaJet Tropis device), ICVAX (TriGrid device)
- Where
- Hong Kong
- Volunteers
- 22 people
- Sponsor
- Immuno Cure Holding (HK) Limited
Human Immunodeficiency Virus I Infection, Human Immunodeficiency Virus II Infection
A Study to Evaluate the Performance of INSTI® HIV Self Test When Performed by Unobserved Intended Users in the US
The objective of this study is to evaluate the performance of INSTI® HIV Self Test with unobserved intended user population. The purpose of this study is to document if a lay person, unassisted by a healthcare worker, is able to…
- Trial name
- NCT07061912
- Testing
- NSTI® HIV Self-Test
- Where
- Canada
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Infection, Human Immunodeficiency Virus
Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects
Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration of a combination of antiretroviral drugs to reduce the patient's HIV levels.
- Trial name
- NCT02373930
- Testing
- DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus I
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects
The purpose of this study is to evaluate the safety and efficacy of the CCR5 antagonist GW873140 or placebo in combination with an optimized background regimen in treatment-experienced HIV-infected subjects with R5-tropic virus
- Trial name
- NCT00197145
- Testing
- GW873140
- Where
- 55 sites in United States, Canada and 1 more
- Volunteers
- 24 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
GSK has in-licensed a novel NNRTI-class candidate (GSK2248761, IDX12899) for the treatment of subjects with HIV-1 infection from Idenix Pharmaceuticals.
- Trial name
- NCT00945282
- Testing
- GSK2248761, Lopinavir/ritonavir, HAART
- Where
- Argentina
- Volunteers
- 8 people
- Sponsor
- ViiV Healthcare
HIV I Infection, HIV-2 Infection
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
The objective of this study is the collection and testing of clinical samples to determine the clinical performance of the Access HIV Ag/Ab Combo assay on the DxI 9000 Access Immunoassay Analyzer
- Trial name
- HIV-EU-11-18 (NCT04971343)
- Testing
- Access HIV_blood donor, Access HIV_Hospitalized patient, Access HIV_known HIV-1 antibody positives
- Where
- 6 sites in France
- Volunteers
- 8,650 people
- Sponsor
- Beckman Coulter, Inc.